Aspire Biopharma Holdings, Inc.
ASBP
Rank in Stocks
#28943
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise... Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Share Price
$8.80
Last synced: 2026-11-11
Market Cap
$9.13M
Change (1 day)
3.29%
Change (1 year)
-93.08%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Aspire Biopharma Holdings, Inc. (ASBP)
Category
Healthcare
EPS for Aspire Biopharma Holdings, Inc. (ASBP)
EPS as of June 2026 TTM: $-8.02
According to Aspire Biopharma Holdings, Inc.'s latest financial reports, its current EPS (TTM) is $-8.02. At the end of 2025 the company had an EPS of $-16.38, an increase over its 2024 EPS of $-34.17.
EPS history for Aspire Biopharma Holdings, Inc. from 2021 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-8.02 | -51.04% |
| 2025 | $-16.38 | -52.06% |
| 2024 | $-34.17 | -467.02% |
| 2023 | $9.31 | 150.27% |
| 2022 | $3.72 | -10,073.19% |
| 2021 | $-0.04 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | -88.90% |
US
|
|
| $15.66 | -295.26% |
US
|
|
| $-7.07 | -11.85% |
US
|
|
| $-5.29 | -34.04% |
AU
|
|
| $12.73 | -258.76% |
BE
|
Questions about Aspire Biopharma Holdings, Inc.'s earnings per share (EPS)
What is Aspire Biopharma Holdings, Inc.'s earnings per share (EPS)?
Aspire Biopharma Holdings, Inc.'s earnings per share (EPS) over the last twelve months is $-8.02, as of Jun 2026.
What was Aspire Biopharma Holdings, Inc.'s earnings per share (EPS) in 2025?
In 2025, Aspire Biopharma Holdings, Inc.'s earnings per share (EPS) was $-16.38, compared with $-34.17 in 2024.
How has Aspire Biopharma Holdings, Inc.'s earnings per share (EPS) changed since 2021?
From 2021 to 2025, Aspire Biopharma Holdings, Inc.'s earnings per share (EPS) was highest in 2023 ($9.31) and lowest in 2024 ($-34.17).
How does Aspire Biopharma Holdings, Inc.'s earnings per share (EPS) compare with similar companies?
Aspire Biopharma Holdings, Inc.'s earnings per share (EPS) ($-8.02) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.